Regeneron Reveals Four New Immunology Antibodies as Sanofi Talks Continue, Flags Q4 Data Readouts for PNH and Geographic Atrophy
Morgan Stanley 24th Annual Global Healthcare Conference, September 14, 2026
Regeneron used its slot at Morgan Stanley's healthcare conference to lay out the broadest public accounting yet of its post-Dupixent immunology pipeline, while confirming that renegotiation of its profit-share arrangement with Sanofi remains unresolved months after both companies flagged the issue on their second-quarter calls. CFO Christopher Fenimore, commercial chief Marion McCourt and IR head Ryan Crowe fielded questions from analyst Terence Flynn on everything from Dupixent's growth ceiling to the looming cemdisiran launch in myasthenia gravis, EYLEA HD's biosimilar defense, and capital deployment priorities.
Four New Antibodies Aim to Extend Dupixent's Franchise
The most concrete new disclosure came from Crowe, who detailed four antibodies in development designed to protect and extend Regeneron's leadership in immunology and inflammation beyond Dupixent's current label. The pipeline includes a long-acting IL-13 antibody already dosing in healthy volunteers ahead of an atopic dermatitis study, a longer-acting antibody targeting the same receptor as Dupixent expected to enter the clinic by late 2026 or early 2027, and two additional programs slated for 2027 entry — one targeting the IL-4 ligand and a bispecific hitting both IL-4 and IL-13. "We feel that between those four antibodies, we have an ability to really cover most, if not all, of the ground that Dupixent currently does, as well as potentially some other indications we have in mind for these programs," Crowe said.
Beyond that cluster, Regeneron disclosed a fifth, undisclosed-target antibody currently dosing in healthy volunteers that the company believes could address a cluster of genetically linked autoimmune conditions — including primary biliary cholangitis, systemic lupus, ulcerative colitis and Sjogren's disease — where the company has identified roughly seven or eight diseases with strong genetic linkage. A Phase II start is targeted for 2027. Notably, management downplayed inflammatory bowel disease as a strategic priority despite an ongoing biomarker-selected Phase II study of Dupixent in ulcerative colitis, with Crowe noting bluntly, "we haven't had a lot of success with Dupixent in ulcerative colitis... I wouldn't say there's any particular goal to enter the IBD space."
Sanofi Renegotiation Still Unresolved, No Timeline Given
Despite market expectations that the Dupixent profit-share restructuring with Sanofi would move toward resolution, Fenimore offered no new clarity on timing. He characterized the process as requiring both sides to walk away feeling they gained something — Regeneron wants changes on economics, while McCourt's commercial team is pushing for operational adjustments. "We continue to make progress with our colleagues at Sanofi... In terms of timing, I don't think there's much we can say as of right now," Fenimore said, adding only that both teams are "working extremely hard." The lack of a firm date is likely to frustrate investors who had hoped for an update following comments on both companies' second-quarter calls. Separately, Sanofi's independent decision to raise its 2030 Dupixent guidance to EUR 25 billion from EUR 22 billion was reaffirmed by McCourt as directionally consistent with Regeneron's own view, with atopic dermatitis — still only in the high teens to 20% penetrated in the U.S. — cited as the single biggest source of remaining headroom.
Cemdisiran Launch Readiness and Three Separate Data Catalysts in Q4
With a PDUFA date in November for cemdisiran in generalized myasthenia gravis, McCourt confirmed the company has built out a dedicated neurology business unit and is "launch ready." She positioned cemdisiran's quarterly dosing as a key differentiator against existing C5 inhibitors, while declining to commit to a more favorable vaccination requirement on label, saying only that trial design differences "would be an interesting point of potential discussion." European approval is not expected until the second half of 2027.
More consequential for the stock are two additional cemdisiran readouts due in the fourth quarter. The PNH Phase III study, combining cemdisiran with pozelimab against eculizumab, carries dual primary endpoints — LDH-based disease control and transfusion avoidance — that both need to hit. Crowe expressed confidence on the disease-control endpoint based on prior normalization data but flagged transfusion avoidance as "a trickier endpoint" given that not all transfusions are driven by the C5-mediated mechanism the drug targets.
The interim geographic atrophy data carries more binary risk. This is a systemic (not intravitreal) approach, an angle where, as Crowe acknowledged, "systemic approaches in the past have failed." The company is drawing on complement knockdown data from its gMG program — "we've demonstrated over 99% knockdown of CH50 in our gMG pivotal study" — as rationale for optimism, but conceded the interim 225-patient readout at 26 weeks could go anywhere from a full washout to a clear success, with the outcome determining whether one of the two active treatment arms gets dropped from the larger 750-patient registrational cohort already enrolling.
EYLEA HD Momentum Builds as Biosimilar Patent Fight Reaches Key Dates
EYLEA HD now represents roughly 60% of combined EYLEA/EYLEA HD U.S. net sales, up from 50% in the first quarter, with McCourt crediting label expansions — Q4-weekly dosing, the RVO indication, and Q20-weekly durability data — for giving the franchise "the broadest label in the anti-VEGF category." Management flagged more competitive intensity in the second half and additional 2-milligram biosimilar entrants as a 2027 headwind, a caution that tempers the otherwise constructive HD conversion story.
On the more consequential 8-milligram biosimilar threat, Crowe provided the clearest timeline yet on the Alvotech patent challenge: depositions are underway now, oral arguments before the PTAB are scheduled for December 4, with a decision expected in early March 2027. He characterized three possible outcomes — full upholding, full invalidation, or a mixed ruling — and emphasized that Regeneron holds additional patents on the 8-milligram formulation extending to 2039, layered with pending applications, meaning a single adverse ruling would not necessarily clear the path for biosimilar entry. Separately, the company still expects prefilled syringe approval at one or more contract manufacturers by year-end, and its internal Saratoga, New York fill-finish facility should begin producing clinical-scale product by year-end as well, with larger commercial-scale lines coming online through 2027.
Capital Allocation Signals a Buyback-First, Not Dividend-Growth, Story
Fenimore was explicit that the dividend, raised only modestly to $0.94 per share from $0.88 since the program's 2025 launch, is not intended as a growth vehicle: "it's not really going to be at least in the short and medium term, a dividend growth story." The company instead leans on opportunistic buybacks, having repurchased roughly $2 billion of stock in the first half of 2026, including $1.2 billion in the second quarter alone, with $2.5 billion of authorization remaining under a valuation-sensitive purchase grid. On business development, Fenimore pushed back on the market's perception that Regeneron only pursues platform deals, noting the company has "kicked the tires" on several later-stage, single-asset opportunities but has walked away over valuation discipline — a signal that large, near-term M&A should not be a base-case investor expectation despite the balance-sheet capacity to act.
Lynozyfic Early Feedback Strong, But Earlier-Line Expansion Is the Real Prize
McCourt described strong physician feedback on Lynozyfic in fourth-line-plus multiple myeloma, citing efficacy, safety and lower hospitalization burden relative to competing bispecifics, but was candid that the near-term late-line opportunity is secondary to the bigger prize of moving into earlier treatment lines, which will require additional trial completions before label expansion becomes possible.